Studies have shown that in breast cancer, lncRNA DILA1 directly binds to cyclin D1, preventing its phosphorylation at the Thr286 site, thereby inhibiting its degradation and increasing the proliferation of breast cancer cells and promoting resistance to tamoxifen.705 Additionally, lncRNAs can act as competing ceRNAs, binding to specific miRNAs and thus alleviating the inhibition of their target mRNAs, which enables them to regulate the sensitivity to targeted therapy. This evidence concerns the gene CCND1 and breast carcinoma.